Study of GSK’s COPD Combination Therapy Relvar Ellipta Shows Positive Results

GlaxoSmithKline (GSK) recently presented data showing that its combination drug Relvar Ellipta (fluticasone furoate and vilanterol) causes a statistically significant reduction in the rate of severe lung exacerbations in patients in the Salford Lung Study (SLS), which assessed the safety and effectiveness of the drug in patients with chronic obstructive pulmonary disease (COPD).

Promising COPD Data Revealed for Relvar Ellipta in Salford Lung Study

GlaxoSmithKline (GSK) and Innoviva (INVA) recently published promising data about the Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD). The clinical trial demonstrated that Relvar Ellipta (fluticasone furoate and vilanterol) could reduce exacerbations compared to usual care, for people with COPD. Usual care involved long-acting muscarinic antagonists (LAMA), long-acting beta2-agonists…